News

Click here to return to the news listings page.

Dr. Dan Fagan Joins Brocair Partners as Senior Advisory Director
8th Jun 2011

Brocair Partners LLC, an investment bank serving the healthcare industry, is pleased to announce that Dr. Dan Fagan has joined as Senior Advisory Director.

NEW YORK, NY – May 24, 2011 – Brocair Partners LLC, an investment banking firm serving the global healthcare industry, is joined by Dr. Dan Fagan.

Dr. Fagan will take on the role of Senior Advisory Director and is a tremendous addition to the Brocair team.

Dr. Fagan was appointed as a director of Synthetech, Inc. in 2001 and was Chairman of the Board from 2005 until the company was sold to W.R. Grace & Co. in November 2010. Between November 2006 and June 2008, Dr. Fagan served as the Chief Executive Officer of Synthetech.

Dr. Fagan was formerly President and CEO of PepTx, Inc., a private early stage pharmaceutical company that is developing peptide based oncology therapeutics. Dr. Fagan continues to serve as a director of PepTx. Prior to PepTx, Dr. Fagan was President of ProGen Biologics LLC, a private biopharmaceutical company that develops healthcare solutions for people suffering from autoimmune diseases. In addition, since 2000, Dr. Fagan has also served as a consultant to the pharmaceutical and emerging pharmaceutical industries.

From 1992 to 2000, Dr. Fagan was employed as the General Manager of Peptides by Mallinckrodt, Inc., a subsidiary of Tyco International that manufactures bulk pharmaceuticals. From 1978 to 1991, he was employed in various capacities, including President, from 1987 to 1991, of Sigma Chemical, a subsidiary of Sigma Aldrich Corporation that manufactures fine chemicals.

Dr. Fagan holds a B.A. in Chemistry from Otterbein College and a Ph.D. in Chemistry from Case Western Reserve University.

Dr. Fagan may be contacted by phone (314-954-6554) or email (dfagan@brocair.com).


For more information, please contact Stas Michael on +44 (0)207 881 2990 or
email stasmichael@mergers-alliance.com.